Company / PP&E (Net)
ROCKET PHARMACEUTICALS, INC. PP&E (Net) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$28.2M
FY2025
5-year range
$22.3M / $39.2M
FY2021-FY2025
Trend
-23.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has fluctuated over the past 8 years, ranging from $2M in FY2018 to $39M in FY2023.
Based on SEC 10-K filings.
$28M in FY2025 with a 5-year CAGR of +8.0%.
Declined from $39M to $28M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -1.0%
- 5-Year CAGR
- +8.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +8.0%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 23.4% year-over-year.
- Peak pp&e (net) was recorded in FY2023.
- Lowest pp&e (net) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $28.2M | -23.4% |
| FY2024 | $36.8M | -6.1% |
| FY2023 | $39.2M | +35.0% |
| FY2022 | $29.0M | +30.1% |
| FY2021 | $22.3M | +16.1% |
| FY2020 | $19.2M | -34.4% |
| FY2019 | $29.3M | +1345.2% |
| FY2018 | $2.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026